Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From Baseline

Loading news article.

Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From Baseline | WAPE

Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From Baseline

Article summary

Related companies

Comments —